Document is current

Article History

First Online: 3 July 2025

Declarations

:

: SA is an employee of GSK/ViiV Healthcare, and has received grants or contracts from the Society for Healthcare Epidemiology of America (SHEA), Centers from Disease Control and Prevention, and the National Institutes of Health—National Institute of Diabetes and Digestive and Kidney Diseases. She has received consultancy fees from the Infectious Diseases Society of America (IDSA), Biomerieux, GSK, Locus Biosciences, Sysmex America, and honoraria for presentations from Brooks Army Medical Center, Virginia Commonwealth University, SOVAH Danville Medical Center, Belmont University, GSK, Northwestern University, and the University of Pittsburgh. Financial support for attending meetings has been provided by SHEA/IDSA, DICON hospitals, Belmont University, Washington University, and Virginia Commonwealth University. She has received payment for participation in advisory boards for Biomerieux and from SHEA, the LEAP Fellowship, IDSA, and the American Society for Healthcare Engineering for participation in other boards, societies, committees or advocacy groups.GB has received consultancy fees from GSK, Hoechst Marion Roussel, IBSA, Janssen-Cilag AG, OM Pharma, and Zambon SpA, and honoraria for presentations from IBSA, OM Pharma and Sun Pharma. He has received financial support for meeting attendance from GSK, Hoechst Marion Roussel, IBSA, Janssen-Cilag AG, OM Pharma, and Zambon SpA, and for participation in advisory boards from IBSA, Janssen-Cilag AG and OM Pharma.MB has no conflicts of interest.RC has received a research grant from Shionogi, and honoraria for presentations from GSK, Menarini, MSD and Shionogi.BG has received honoraria for presentations from Advanz, Gilead, Infectopharm, MSD, Pfizer and Shionogi and for participation in advisory boards from MSD and Pfizer.KG serves as a consultant for GSK, Iterum Therapeutics, Utility Therapeutics, VenatorX, PhenUTest, and Qiagen and receives royalties from UpToDate on UTI topics, and is an uncompensated member of the IDSA UTI Guideline Committee.SG has received consultancy fees from Immunotek and Biomerieux.JH has acted as a consultant to Advanz, Mundipharma, Alifax, Menarini, and TFT Pharmaceuticals. He has received honoraria for presentations from Alifax, GSK, MSD and Pfizer, and support for attending meetings from MSD, Pfizer and Shionogi. He has been paid for his attendance at advisory boards and involved in a clinical trial sponsored by DSMB and TFT Pharmaceuticals.PK has acted as an advisor to GSK and received honoraria from GSK and AstraZeneca for presentations, and financial support from GSK for attending meetings.NN has received research grants from Merck and Shionogi, and honoraria for presentations from Astellas and Beckman-Coulter.FW has acted as an consultant to GSK, VenatoRX and Advance Pharma and was a principal investigator in a GSK-sponsored study. He has received honoraria for presentations from Astellas, AstraZeneca, Bionorica, GSK, Janssen, Klosterfrau, MPI-Pharma, OM-Pharma, and Pfizer. He has received financial support from Bionorica, GSK and MIP-Pharma for attendance at meetings and has been involved in the development of the German S3 guideline for urinary tract infection and the European Association of Urology guidelines for urological infections.MW has received consulting fees from Astra Zeneca, BioInteractions, Debiopharm, Ferring, GSK, Nestlé, Paion, Pfizer, Phico Therapeutics, Qpex Biopharma, Seres, Summit, The European Tissue Symposium, Tillotts, and Vedanta; lecture fees from GSK, Pfizer, Seres & Tillotts; and grant support from Debiopharm, GSK, Pfizer, Seres, Summit, The European Tissue Symposium and Tillotts.MS has acted as a consultant for ASHP, Basilea/3D consulting, Cidara, DoseMe, Duke/ARLG, Entasis, F2G, GSK, Lykos Therapeutics, National Institutes of Health, Roche, Third Pole Therapeutics, University of Pennsylvania, and Xellia. He has received honoraria for presentations from ASHP, Duke/ARLG, and the National Institutes of Health, financial support for travel from DoseMe and GSK and participated in advisory boards for DoseMe and F2G.